छोड़कर सामग्री पर जाएँ

Biocon shares jump 2% after UK approval to diabetes drug

So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period.

Read More

​ So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period. So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी